Drugs / Ginkgo Biloba Extract
Ginkgo Biloba Extract
also known as
Ginkgobiloba · EGb 761 · GBE · Tanakan · Ginkgo · Ginkgo biloba leaf extract · ginkgo extract · Cerenin(Ginkgo Biloba Extract) film-coated 40 mg · +9 more
Trials 38 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02386852 | Mar → Nov 2014 | — | Sunway University | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT02882438 | Jan 2016 → Sep 2020 | tinea pedis | Al-Azhar University | Unknown | No outcome recorded |
| Phase 1 | NCT01246804 | Nov 2010 → Mar 2011 | HIV infectious disease, cognitive impairment with or without cerebellar ataxia, depressive disorder | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00689858 | May 2007 → Jul 2008 | — | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00011063 | Feb → Apr 2001 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT00032474 | Dec 2001 → May 2005 | type 2 diabetes mellitus | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 1/2 | NCT00029991 | Sep 2000 → Jul 2005 | intermittent vascular claudication | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 1/2 | NCT00029679 | Sep 2000 → Jul 2005 | asthma | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 1/2 | NCT00010842 | Sep 1999 → Dec 2004 | multiple sclerosis | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT04525144 | Oct 2020 → Dec 2025 overdue | cerebrovascular disorder, cognitive impairment with or without cerebellar ataxia | National Neuroscience Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT02376114 | Aug 2011 → Feb 2014 | open-angle glaucoma | Maisonneuve-Rosemont Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00824512 | Jun 2008 → Oct 2011 | Friedreich ataxia | Ipsen | Completed | No outcome recorded |
| Phase 2 | NCT00251238 | Nov 2005 → Mar 2006 | Raynaud disease | VSM Geneesmiddelen b.v. | Completed | No outcome recorded |
| Phase 2 | NCT00500500 | Jul 2005 → Apr 2008 | Alzheimer disease | Ipsen | Terminated | No outcome recorded |
| Phase 2 | NCT00034021 | Jun 2002 → Sep 2004 | hypoactive sexual desire disorder | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2 | NCT00029692 | Mar 2002 → Mar 2005 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07709312 | Jul → Oct 2026 expected | rheumatoid arthritis | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06403787 | May 2022 → Apr 2023 | HIV infectious disease | University of Guadalajara | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT06989697 | Jan 2025 → Dec 2026 expected | CGF1, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03318276 | Feb 2017 → Oct 2018 | peripheral arterial disease | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01536210 | Dec 2011 → Aug 2012 | mental disorder | Yuyu Pharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00276341 | Aug 2003 → Dec 2005 | relapsing-remitting multiple sclerosis | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00276380 | Feb 2003 → Mar 2009 | ischemic stroke | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00046891 | Dec 2002 → Oct 2006 | breast cancer, poisoning | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00010920 | Sep 1999 → Dec 2004 | dementia | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT07579689 | Jun 2026 → Dec 2028 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Hanyang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05445895 | Dec 2022 → Oct 2025 | ischemic stroke | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03483779 | Apr 2018 → Dec 2020 | — | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT01046292 | Jan 2010 → Feb 2015 | cognitive impairment with or without cerebellar ataxia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT01038050 | Oct 2009 → Nov 2010 | coronary atherosclerosis, type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT00103012 | Jan 2005 → Jan 2011 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 4 | NCT00042172 | Jun 2002 → Sep 2004 | Alzheimer disease | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT00276510 | Feb 2002 → Nov 2009 | cognitive disorder, hippocampal sclerosis of aging | Ipsen | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06771128 | Nov 2024 → Dec 2025 | nocturnal enuresis | Menoufia University | Completed | No outcome recorded |
| — | NCT06140888 | Mar 2024 → Oct 2026 expected | ischemic stroke | Yi Yang | Not yet recruiting | No outcome recorded |
| — | NCT05398874 | Nov 2021 → Jun 2022 | osteoarthritis, knee | Kufa University | Completed | No outcome recorded |
| — | NCT04492241 | Jul 2021 → Dec 2023 | cognitive impairment with or without cerebellar ataxia | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| — | NCT04121728 | Sep 2019 → May 2024 | CGF1, subjective cognitive decline | Jean-François Démonet | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02465749 Background | May 2015 → Jun 2025 | retinitis pigmentosa | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03772418 Comparator | May 2018 → Jan 2020 | — | Al-Azhar University | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00164749 Background | Oct 2004 → Jul 2006 | Alzheimer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 1/2 | NCT00070954 Comparator | Feb 2003 → Jan 2005 | — | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02425436 Comparator | May 2014 → Oct 2015 | fetal growth restriction | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT00841321 Comparator | Jan 2009 → Nov 2010 | CGF1, multiple sclerosis | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2 | NCT00814346 Comparator | Oct 2008 → Jul 2012 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Ipsen | Completed | No outcome recorded |
| Phase 2 | NCT01139281 Comparator | Jun 2007 → Jun 2008 | platinum-induced ototoxicity | University of Brasilia | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02098330 Comparator | Mar → Dec 2014 | vestibular neuronitis | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00010803 Comparator | Oct 2000 → Apr 2008 | Alzheimer disease | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 3 | NCT01637168 Comparator | — | — | EMS | Withdrawn | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06772584 Comparator | Jan → Jul 2024 | nocturnal enuresis | Menoufia University | Completed | No outcome recorded |
| — | NCT06124703 Background | Nov 2023 → Feb 2024 | sensorineural hearing loss disorder, tinnitus | Eye & ENT Hospital of Fudan University | Unknown | No outcome recorded |
| — | NCT07283562 Comparator | Jan 2023 → Oct 2025 | sensorineural hearing loss disorder | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
| — | NCT05591144 Background | Oct 2022 → Jan 2023 | tinnitus | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT05258123 Comparator | May 2017 → Jun 2018 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT03425045 Comparator | Mar 2015 → Mar 2018 | tinnitus | University Hospital Ostrava | Completed | No outcome recorded |
| — | NCT01663467 Background | Sep 2014 → Sep 2016 | tinnitus | Seoul National University Hospital | Withdrawn | No outcome recorded |
| — | NCT01524380 Comparator | Sep 2011 → Jun 2013 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginkgo biloba extract | “Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg),...” NCT06989697 ↗22“Ginkgo biloba extract not only is a commonly used drug for cardiovascular diseases, but also has a significant effect in reducing blood sugar.” PMID 30405743 ↗ Oct 2018 “We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia” NCT05258123 ↗ “Both groups received a standard regimen (Dextran-40, Ginkgo Biloba Extract, Mecobalamin, and Yufeng Ningxin Dripping Pills).” NCT07283562 ↗ “Ginkgo biloba extract (EGb 761) has also been reported to improve neurological impairment following AIS.” PMID 39528058 ↗ Nov 2024 “Ginkgo biloba extract (GBE), a naturally occurring substance from the ancient Chinese Ginkgo tree” NCT00034021 ↗ |
| Known as | Cerenin(Ginkgo Biloba Extract) film-coated 40 mg | “Cerenin(Ginkgo Biloba Extract) film-coated 40 mg” NCT01038050 ↗ |
| Known as | EGb | “The extract of G. biloba (EGb) is composed of different terpene trilactones, i.e., ginkgolides A, B, C, J and bilobalide, many flavonol glycosides, biflavones and alkylphenols” NCT02425436 ↗ |
| Known as | EGb 761 | “The objective of this study was to compare the effects of 300 mg/d of Ginkgo biloba (EGb 761) versus placebo on treadmill walking time and related cardiovascular measures among...” PMID 18628657 ↗ Jul 200814“Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.” NCT03425045 ↗ “A standardized Ginkgo biloba extract, EGb 761, may have protective effect against cisplatin-induced ototoxicity in rats.” PMID 17450108 ↗ Sep 2007 “Ginkgo biloba extract (EGb 761) has also been reported to improve neurological impairment following AIS.” PMID 39528058 ↗ Nov 2024 “1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ “twice per day dose of 120 mg standardised ginkgo biloba extract (EGb761) or matched placebo.” PMID 22959217 ↗ Sep 2012 “EGb 761® 120 mg bid, orally for 12 to 14 weeks” NCT00824512 ↗ “Dietary supplement: Gingko biloba EGb 761” NCT04525144 ↗ “Dietary supplement: Gingko biloba EGb 761” NCT04525144 ↗ |
| Known as | GBE | “This study will also determine whether adding ginkgo biloba extract (GBE) enhances the effects of donepezil.” NCT00042172 ↗2“Ginkgo biloba extract (GBE), a naturally occurring substance from the ancient Chinese Ginkgo tree” NCT00034021 ↗ “standardized ginkgo biloba extract (GBE)” NCT00010920 ↗ |
| Known as | GBLE | “Ginkgo biloba leaf extract (GBLE) has an antioxidant action as a free radical scavenger, an improving effect on blood flow or microcirculation, and a stimulating effect on...” NCT07709312 ↗ |
| Known as | Gingko biloba | “Gingko biloba is a complementary or alternative medication used for purported cognitive enhancing effects.” NCT00011063 ↗ |
| Known as | Ginkgo | “The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of...” NCT02376114 ↗ |
| Known as | Ginkgo biloba extract EGb 761 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00251238 ↗ |
| Known as | Ginkgo biloba leaf extract | “Ginkgo biloba leaf extract (GBLE) has an antioxidant action as a free radical scavenger, an improving effect on blood flow or microcirculation, and a stimulating effect on...” NCT07709312 ↗1“Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks” NCT03318276 ↗ |
| Known as | ginkgo extract | “YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication” NCT01536210 ↗1“1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ |
| Known as | ginkgo leaf extract | “All patients also received 120 mg/day standardized ginkgo leaf extract.” NCT00164749 ↗ |
| Known as | Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04492241 ↗ |
| Known as | Ginkgobiloba | “Ginkgo biloba has been reported to increase maximal and pain-free walking distance among patients with PAD; however, the evidence is inconsistent.” PMID 18628657 ↗ Jul 200823“Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States.” NCT06772584 ↗ “Ginkgo biloba, a flavonoid-rich extract of leaves of the Ginkgo biloba tree” NCT00029679 ↗ “Ginkgo Biloba 120 mg twice daily for 14 days” NCT00103012 ↗ “Ginkgo Biloba in different dosage forms” NCT02882438 ↗ “Drug: Ginkgobiloba” NCT06772584 ↗ |
| Known as | GINKO BILOBA | “GINKO BILOBA Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States.” NCT06772584 ↗ |
| Known as | LIFE EXTENSION | “240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets” NCT06403787 ↗ |
| Known as | Tanakan | “EGb 761® (Tanakan®)” NCT00500500 ↗ |
| Known as | Tebonin | “Ginkgo Biloba (Tebonin®)” NCT01637168 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging.” PMID 20040554 ↗ Dec 2009 |
| Route | Oral | “supply of 60-mg capsules of ginkgo to take twice a day (at 8 A.M. and 8 P.M..)” NCT00011063 ↗ |